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Primary central nervous system lymphomas (PCNSL) are extralnodal lymphomas arising from brain parenchyma, meninges, the spinal 
cord or eyes in the absence of any systemic involvement 
by lymphoma.1 PCNSL accounts for 4% of all primary 
malignant neoplasia of the central nervous system and 
4% to 6% of extralnodal lymphomas.2 The incidence of 
PCNSL lymphoma has been steadily rising during the 
past three decades, increasing from 2.5 per million in 
1973 to 30 per million in 1997.1l3 The risk factors for 
PCNSL have included acquired or hereditary immune 
deficiency states i.e. infection with human immune defil
ciency virus, organ transplantation, severe combined iml
mune deficiency, ataxia telengiectasia, WiskottlAldrich 
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BACKGROUND: primary cns lymphoma (pcnsl) is an aggressive primary brain tumor. cranial irradiation 
alone rarely results in long term disease control or prolonged survival. We retrospectively analyzed data on the 
effect of adding high-dose methotrexate (hdmtX) prior to whole brain irradiation (Wbi). 
METHODS: all patients with pcnsl diagnosed and managed during 1991-2004 were identified and demo-
graphic characteristics, prognostic factors, treatment and outcome were reviewed. of 62 patients, 10 were ex-
cluded (4 had Wbi <40 Gy and 6 had no treatment). radiation alone was considered curative with a dose >40 
Gy. combined modality therapy included 3-4 cycles of hdmtX (3 g/m2) followed by Wbi.
RESULT: of 52 patients analyzed for outcome, 36 had Wbi (dose >40 Gy), 16 received 3-4 cycles of hdmtX 
followed by Wbi (combined modality therapy [cmt]). median age was 48.2 years; 42 years in the cmt group, 
51 years in Wbi. patient characteristics were comparable between two groups except for higher multifocal 
tumor in the cmt group (92% vs. ×22%, p=.029). median follow up was 12.83±6.4 months. the hazard ra-
tio for an event was 0.64 (95% ci, 0.52-0.98) and for death 0.58 (95% ci, 0.48-0.92), both in favor of cmt. 
univariate regression analysis using one-way analyses of variance (anoVa) and multivariate cox regression 
analysis for prognostic factors including age (<60 vs. >60), ecoG ps (0-2 vs. 3-4), extent of surgery (biopsy vs. 
debulking), solitary vs mutifocal tumor and dose of radiation therapy (<50Gy vs. >50Gy) failed to identify any 
prognostic factor.
CONCLUSION: this retrospective comparison supports phase ii trial results that indicate that high-dose metho-
trexate followed by Wbi in pcnsl improves outcome. 
syndrome as well as autoimmune or inflammatory disl
orders requiring long term immune suppression such 
as rheumatoid arthritis, systemic lupus erythematosus, 
Sjogren syndrome, myasthenia gravis and vasculitides.4l7
Although the pathology of PCNSL is diffuse large 
B cell in 95% of the cases, other histologies like Tlcell 
lymphomas, anaplastic large cell and even indolent hisl
tologies are regularly encountered.8,9 Unfortunately no 
prospective randomized controlled data are available to 
guide the management of PCNSL and most experience 
comes from small prospective phase II studies and retl
rospective series.10l17 Traditionally PCNSL was treated 
with whole brain radiation therapy (WBRT) with 
a median overall survival of 16 months.17 However, a 
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metalanalysis of 1180 patients from 50 series published 
in 1997 suggested that survival may be better when 
treated with a combined modality approach including 
chemotherapy and radiation.18 Adding to this control
versy has been several reports stating that survival may 
be equivalent or even better with chemotherapy alone, 
thus avoiding the longlterm toxicity from whole brain 
radiotherapy.19 Important issues that remain unanl
swered are type of chemotherapy, single agent versus 
combination chemotherapy, dose and technique of ral
diation therapy, and the role if any of monoclonal antil
body therapy, especially in B cell lymphoma.
At our institution, PCNSL was treated with WBRT 
until 2001 when we changed our guidelines to include 
chemotherapy and radiation as part of primary manl
agement of PCNSL. We therefore decided to review 
our results with combined modality therapy. 
METHODS
After obtaining approval from our institutional review 
board, we identified all patients diagnosed and treated 
with primary central nervous system lymphoma from 
the Oncology Data Unit at our institution from 1994 
to 2004. For inclusion into this analysis, patients older 
than 18 years of age had to have a confirmed histologic 
diagnosis of central nervous system lymphoma in the 
absence of any radiologic evidence of systemic involvel
ment. The patient had to have a followlup of 6 months 
to be included in this analysis. Patients with any conl
genital or acquired immune deficiency states including 
HIV or therapeutic immunelsuppression were excludl
ed. Data on age, sex, histology, performance status at 
diagnosis, location of lesions (deep versus superficial), 
type of surgery (biopsy versus debulking) and multil
plicity of lesions as well as primary treatment and treatl
ment intent were collected.
Chemotherapy consisted of highldose methotrexate 
at a dose of 3 g/m2 at two weekly intervals for a total 
of 4 cycles. Standard precautions with aggressive prel
chemotherapy hydration and alkalization of urine as 
well as postlchemotherapy rescue with intravenous and 
oral folinic acid were instituted until serum methotrexl
ate levels became nontoxic according to our laboratory 
reference ranges.
Radiation therapy was considered to have been del
livered with curative intent if the total dose exceeded 
4000 Gy given over at least 4 weeks to the whole brain 
(180l200 cGy/fraction, 5 fractions per week). The ral
diation was given in two parallel opposed fields using 
6l10 MV linear accelerator machine. Radiation given 
at a total dose lower than 4000 cGy was considered to 
have been delivered with palliative intent. In combined 
modality group radiation had to start within 4 weeks of 
the last cycle of chemotherapy.
The patients underwent MRI scan of the brain at 
diagnosis as well as CT scans of the chest, abdomen 
and pelvis and lumbar puncture at diagnosis. A repeat 
MRI scan to assess response was done after the end of 
chemotherapy in those who were managed with coml
bined modality therapy. All patients had evaluation of 
response at the end of all planned treatment with an 
MRI and were then followed at 3 monthly intervals 
with a followlup MRI scan as well as clinical evaluation 
to assess residual neurologic deficit and/or longlterm 
toxicity from treatment.
All statistics were performed with SPSS software 
Table 1. Patient characteristics (n=62).
Factor Number %
Age
  Median 48.2
  Range 29-76
Gender
  Male 34 54.8
  Female 28 45.2
Performance status
  0-2 21 33.9
  3-4 41 66.1
Lesions
  Solitary 46 74.2
  Multiple 16 25.8
Surgical
  Debulking 22 35.5
  Biopsy 40 64.5
Pathology
  DLBCL 57 91.9
  PTCL 3 4.8
  Follicular 1 1.6
  Immunological 1 1.6
Primary treatment
  CRT 16 25.8
  XRT 36 58.1
  Palliative treatment 10 16.1
DLBCL: diffuse large B cell lymphoma, CRT: chemo + radiation therapy,  XRT: external 
radiation therapy
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(version 11). Description statistics are presented as numl
ber and percentage (frequency distribution). The Fisher 
exact test was used to compare the results for significance 
with a P value of <.05 considered a significant result. A 
complete response (CR) was defined as disappearance 
of all evidence of tumor, and with the patient free of all 
diseaselrelated symptoms. A partial response (PR) was 
defined as a >50% reduction in the sum of the products 
of the diameters of all measurable lesions, without an 
increase in size or new lesions appearing. Stable disease 
(SD) was defined as no change or <25% in the sum of 
the products of the diameters of any measurable lesions. 
Progressive disease (PD) was defined as an increase of 
>25% in the sum of the products of the diameters of 
any measurable disease or unequivocal appearance of 
new lesions. Overall survival (OS) was defined as time 
from date of diagnosis to date of last follow up or death. 
Eventlfree survival (EFS) was defined as time from date 
of diagnosis to date of initiation of additional treatment 
or relapse, where residual disease after treatment, time 
to change in treatment or death were considered to be 
events. Timeltolprogression (TTP) was defined as time 
from date of achieving CR or PR to date of recurrence or 
distant metastasis. Cox regression analysis was used for 
univariate and multivariate analysis of factors affecting 
survival, with a P value of <.05 indicating significance. 
The KaplanlMeier method was used to determine surl
vival curves, and the loglrank test was used to compare 
survival in different populations, with a P value of <.05 
indicating significance.
RESULTS
We identified 62 patients treated from 1994 to 2004 who 
fulfilled the criteria for inclusion. There were 34 males 
and 28 females with an almost equal maleltolfemale ral
tio. Median age was 48.2 years (range 29l76). Sixtylsix 
percent (n=41) had an ECOG performance status of 
greater than 2, while 34% had a performance status of 
0l2. Fortylsix patients (74%) presented with a solitary lel
sion and 16 (26%) had multiple lesions at presentation.
Diffuse large B cell lymphoma (DLBCL) was the 
predominant histology (n=57, 92%). Other subtypes 
included peripheral T cell lymphoma in 3 patients 
(4.8%), follicular lymphoma and immunoblastic lyml
phoma in one patient each (Table 1).
Treatment consisted of combined modality therapy 
(CMT) in 16 (26%), radiation therapy with curative 
intent in 36 patients (58%) and radiation therapy with 
palliative intent in 10 (16%). To eliminate bias towards 
CMT we excluded 10 patients treated with palliative 
intent from further analyses and present the response 
and survival data on patients treated with CMT and 
Table 2. Patient characteristics by group.
Factor
Combined 
therapy (n=16)
Radiation 
therapy (n=36) P
No. % No. %
Age
  Median 42 51.9 .56
Gender
  Male 11 68.8 19 52.8 .2
  Female 5 31.3 17 47.2
Performance 
status
  0-1 7 43.75 3 8.3 .05
  2-4 9 56.25 33 91.7
Multiple 
lesions
  Yes 15 93.8 22 61.1 .029
  No 1 6.2 14 38.9
Surgery
  Debulking 5 31.3 15 41.7 .38
  Biopsy 11 68.8 21 58.3
Pathology
  DLBCL 16 100 36 100 .18
Table 3. Response rates by group.
   Response
Combined 
therapy (n=16)
Radiation 
therapy (n=36) P
No % No %
   Complete response 7 43.8 13 36.1
 
.50
 
 
   Partial response 5 31.3 7 19.5
   Stable disease 3 18.8 12 33.3
   Progressive disease 1 6.3 4 11.1
Table 4. Recurrence rates by group.
   Recurrence
Combined therapy 
(n=16)
Radiation therapy 
(n=36) P
No. % No. %
   Yes 3 18.8 18 50
 
.01   No 11 68.8 9 25
   NA 2 12.5 9 25
   Time-to- 
   progression 11.8 months 4.8 months .06
DLBCL: Diffuse large B cell lymphoma
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DISCUSSION
In this retrospective series, the median OS and EFS for 
the entire group was 11 and 8 months, respectively. OS 
was significantly longer (45 months) for the CMT group 
compared to the radiation therapy group (10.5 months) 
(P=.033). EFS was similarly prolonged in the CMT 
group (33.1 months vs. 7.1 months; P=.035). Patients 
who received RT were older, with poorer performance 
and with a higher frequency of multifocal disease. These 
findings were likely responsible for the lower EFS and 
OS and the loss of significance in the multivariate analyl
sis. Our data for CMT is similar to previous results from 
both retrospective analyses and prospective trials.12,15,20l
24 In an Australian phase II trial, patients who received 
two cycles of highldose methotrexate (1 g/m2) followed 
by 45 Gy of whole brain external radiation therapy 
(WBXRT) had an OS of 33 months.23 Similarly in a 
Radiation Therapy Oncology Group (RTOG) study, 
patients who were given more prolonged methotrexatel
based chemotherapy and WBXRT (45 Gy) followed by 
highldose cytarabine had a median OS of 37 months.15 
A retrospective analysis of 357 patients reported in 
19 prospective series, reported that patients receiving 
methotrexate at doses ≥3 g/m2 had a significantly longer 
median survival compared with those receiving <3 g/m2 
(P=.04).25 There was no difference in overall survival 
(OS) among those receiving single agent chemotherapy 
and combination chemotherapy (P=.38). Of the 119 
complete responders, 70 received immediate RT. A RT 
dose of ≥40 Gy to the whole brain or tumor bed did 
not improve OS. The 3lyear OS was similar between 
the immediate and delayed RT groups. In a multivariate 
analysis, RT delay had no negative impact on survival.25 
Somewhat similar results were noted in a multicenter 
study reporting on survival data in 370 patients treated 
at 23 different centers.19 Patients treated with radiation 
therapy alone had the worst twolyear OS (25 percent), 
whereas those treated with high doses of methotrexate 
and cytarabine had the best survival (64 percent). 
The overall survival with combined modality therapy 
appears to be superior to that in previous reports. This 
may be because our patient cohort belonged to a more 
favorable prognostic group based on the International 
Extranodal Lymphoma Study Group (IESLG) and 
Memorial Sloan Kettering Cancer Center (MSKCC) 
prognostic criteria.26,27 Our patient population consistl
ed predominantly of young patients, with good perforl
mance status. Most of them had undergone debulking 
surgery and 98.5% of them had solitary lesions. All of 
these are favorable prognostic features in IESLG and 
MSKCC prognostic scores for PCNSL. 
Unfortunately, no randomized data exist to prove sul
radiation therapy with curative intent (n=52). In this 
group all histology was DLBCL. Median age was 52 
years in the radiation alone group while it was 42 in the 
CMT group (Table 2). The maleltolfemale ratio was 
2:1 in the CMT group while it was equal in the RT 
group. Nine of 16 patients (56%) in the CMT group 
presented with PS of <2 while 33 of 36 (92%) has PS 
>2 in RT group (P=.05). Multiple parenchymal lesions 
were present in only one patient in the CMT group 
while 14 of 36 in the RT group had multiple lesions 
(P=.029). Surgical debulking was performed in 5/16 
(31%) patients in CMT group and 15/36 (41%) pal
tients in RT group. Surgical intervention consisted of 
biopsy alone in the rest of the patients.
Response and Survival
Overall response rate (CR+PR) was 74% in the CMT 
group and 55% in the RT group. The complete remisl
sion rate was 7/16 (44%) and 13/36 (36%) while the 
partial response rate was 31% (5/16) and 19% (7/36) in 
the CMT and RT groups, respectively (P=.50 for PR). 
One patient in the CMT and 4 in the RT group had 
progressive disease while 3 and 12 had stable disease 
in their respective groups (Table 3). the recurrence rate 
was significantly lower in the CMT group compared to 
the RT group, 19% (3/16) and 50% (18/36), respecl
tively (P=.01). Two patients and one patient in each 
group, respectively, were not assessed for recurrence. 
Median TTP was 11.8 months in the CMT group and 
4.8 months in the RT group (Table 4).
For the entire group, at a median followlup of 
25.7months (SD=19.1 months), the median EFS 
was 8 months (22.5% and 16.8% at 3 and 5 years, 
respectively) (Figure 1). Median OS was 11 months 
(36% and 22% at 3 and 5 years, respectively) (Figure 
2). Median EFS was 33.1 months and 7.1 months 
for CMT and RT, respectively (at 3 years 48.8% and 
22.1% and at 5 years 24.4% and 17.7%, respectively; 
P=.035; HR=0.58 with 95% confidence interval of 
0.48l0.93) (Figure 3). Median OS was 45 months and 
10.5 months for CMT and RT, respectively (at 3 years 
57% and 31.6% and at 5 years 38% and 20.3%, respecl
tively; P=.033; HR=0.64 with 95% confidence interl
val of 0.52l0.98) (Figure 4).
In the univariate analysis of the prognostic impact 
of different factors (primary treatment, age, PS, type of 
surgery, multiplicity of lesions and radiation dose) we 
found primary treatment (CMT vs. RT) and age (<50 
or >50 years) (Figures 5, 6) to have a significant influl
ence on survival (Table 5). Age (as a constant factor) 
was the only significant factor influencing survival on 
multivariate analyses (Tables 6).
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Figure 1. Event free survival whole group.
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Figure 3. Event free survival according to treatment (CRT vs. RT).
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Figure 5. Event free survival according to age (<50 vs. >50).
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Figure 6. Overall survival according to age (<50 vs. >50).
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Table 5. Univariate analysis of prognostic factors.
   Factor
Event-free survival Overall survival
Median P Median P
   Primary 
   treatment
     CRT 33.1
 .035
45
.033
     XRT 7.1 10.5
   Age
     <50 y 14.56 .0001 (CV)a 14.6 .0001 (CV)a
     >50 y 5.43 .025 18.03 .009
   Performance   
   status 
     0-1 14.3
.168
18.03
.16
      2-4 10.5 11.3
   Multiplicity
     Yes 14.3
 .16
14.5
.21
     No 4.9 6.6
   Surgical
     Debulking 11.8
 .75
14.3
.74
     Biopsy 10.5 11.9
   Radiation dose
     >50 Gy 14.3
.26
14.3
.32
     <50 Gy 5.4 7.1
aCV: Continuous variable
CRT: chemo + radiation therapy, XRT: external radiation therapy
Table 6. Multivariate analysis of prognostic factors.
   Factor
EFS OS
P P
   Constant .011 .043
   Primary treatment .51 .49
   Age (cont. variable) .007 .003
   Performance status .2 .34
   Multiplicity .79 .87
   Surgery .71 .66
   Radiation dose .28 .51
periority of one regimen over the other. Chemotherapy 
alone with radiation has also been reported in prospective 
phase II trials. Use of highldose methotrexate (8 g/m2) 
with leucovorin rescue followed by maintenance methol
trexate without radiation therapy, reported a median OS 
of 23% in 23 evaluable patients.12 Similarly a 3 year EFS 
of 35% has been reported in a randomized phase II trial 
of high dose methotrexate ± high dose cytosine arabil
noside.28 A SWOG/RTOG trial of 102 patients with a 
lower dose of methotrexate followed by WBRT reported 
a median OS of 36.9 months (60 and 21.8 months, rel
spectively, for those younger and older than 60 years of 
age).15 A 5lyear OS of 77% has been reported with use 
of highldose chemotherapy and stem cell transplantation 
without RT in a single arm phase II trial.29 
Our analysis failed to show a prognostic impact for 
any factors except age and primary therapy (CMT vs. 
RT alone) in univariate analysis while on multivariate 
analysis, age alone appeared to be the prognostic factor. 
We did not have enough data to analyze the impact of 
other prognostic factors reported by IESLG (LD, bone 
marrow involvement and CSF cytology).
In conclusion, our data support the previously rel
ported retrospective data and prospective phase II data 
of superiority of combined modality therapy with chel
motherapy and radiation compared to either one alone 
with age alone being the significant factor impacting 
prognosis in our study. Combined chemoradiotherapy 
should therefore be the treatment of choice for newly 
diagnosed primary CNS lymphoma until randomized 
trials provide data to the contrary.
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